|
|
含米诺环素的铋剂四联方案联合复合乳酸菌用于幽门螺杆菌感染根除治疗的回顾性研究
|
Abstract:
目的：评价含米诺环素的铋剂四联方案联合复合乳酸菌在幽门螺杆菌(Helicobacter pylori, H.pylori)感染初治患者中的根除疗效、不良反应等情况。方法：回顾性分析2023年1月至2025年4月于青岛大学附属医院就诊的H.pylori感染患者的临床资料，按照纳排标准将患者分为四组，其中EACB组(211例)：艾司奥美拉唑 + 阿莫西林 + 克拉霉素 + 枸橼酸铋钾 × 14天；EACBL组(191例)：艾司奥美拉唑 + 阿莫西林 + 克拉霉素 + 枸橼酸铋钾 + 复合乳酸菌 × 14天；EAMB组(206例)：艾司奥美拉唑 + 阿莫西林 + 米诺环素 + 枸橼酸铋钾 × 14天；EAMBL组(197例)：艾司奥美拉唑 + 阿莫西林 + 米诺环素 + 枸橼酸铋钾 + 复合乳酸菌 × 14天。随访患者的H.pylori根除情况、不良反应、服药依从性等情况。结果：本研究共纳入805名患者，EACB组211名患者，根除率为84.8% (179/211)；EACBL组191名患者，根除率为90.6% (173/191)；EAMB组206名患者，根除率为97.6% (201/206)；EAMBL组197名患者，根除率为95.9% (189/197)，入组患者中有171人出现不同程度的不良反应，包括口苦、恶心、呕吐、腹胀、腹痛、胃部不适、大便次数增多、腹泻、便秘、头晕、头痛、皮疹等。其中EACB组不良反应发生率为32.2% (68/211)；EACBL组不良反应发生率为13.1% (25/191)；EAMB组不良反应发生率为23.8% (49/206)；EAMBL组不良反应发生率为14.7% (29/197)。结论：1) 本回顾性研究中观察到含米诺环素方案的根除率与更高的根除率相关。2) 加用复合乳酸菌与较低的药物不良反应发生率相关。
Objective: This paper aims to evaluate the eradication efficacy, adverse reactions, and adherence of minocycline-containing bismuth quadruple therapy combined with compound lactobacillus in Helicobacter pylori–naive patients. Methods: A retrospective analysis was conducted on the clinical data of patients with Helicobacter pylori infection who attended the Affiliated Hospital of Qingdao University from January 2023 to April 2025. According to the inclusion and exclusion criteria, the patients were divided into four groups: EACB group (211 cases) received a regimen of esomeprazole, amoxicillin, clarithromycin, and bismuth potassium citrate; EACBL group (191 cases) received a regimen of esomeprazole, amoxicillin, clarithromycin, bismuth potassium citrate and compound lactobacillus; EAMB group (206 cases) was treated with esomeprazole, amoxicillin, minocycline, and bismuth potassium citrate; EAMBL group (197 cases) received esomeprazole, amoxicillin, minocycline, bismuth potassium citrate and compound lactobacillus. All medications were administered for 14 days. The patients were followed up to assess outcomes including Helicobacter pylori eradication status, adverse reactions, and medication adherence. Result: A total of 805 patients participated in this study; the eradication rates of the EACB, EACBL, EAMB and EAMBL groups were 84.8% (179/211); 90.6% (173/191); 97.6% (201/206); and 95.9% (189/197). Among the follow-up patients, 171 experienced adverse reactions of varying degrees, including bitter taste, nausea, vomiting, abdominal distension, abdominal
| [1] | Brito, B.B.d., Silva, F.A.F.D., Soares, A.S., Pereira, V.A., Santos, M.L.C., Sampaio, M.M., et al. (2019) Pathogenesis and Clinical Management of Helicobacter pylori Gastric Infection. World Journal of Gastroenterology, 25, 5578-5589. https://doi.org/10.3748/wjg.v25.i37.5578 |
| [2] | Liu, W.Z., Xie, Y., Lu, H., Cheng, H., Zeng, Z.R., Zhou, L.Y., et al. (2018) Fifth Chinese National Consensus Report on the Management of Helicobacter pylori Infection. Helicobacter, 23, e12475. https://doi.org/10.1111/hel.12475 |
| [3] | Franceschi, F., Covino, M. and Roubaud Baudron, C. (2019) Review: Helicobacter pylori and Extragastric Diseases. Helicobacter, 24, e12636. https://doi.org/10.1111/hel.12636 |
| [4] | 蔺莉, 陶瑞雨, 蔡永刚, 杨文娟. 幽门螺杆菌相关炎症与胃癌[J]. 甘肃医药, 2024, 43(7): 577-581. |
| [5] | Brown, L.M. (2000) Helicobacter pylori: Epidemiology and Routes of Transmission. Epidemiologic Reviews, 22, 283-297. https://doi.org/10.1093/oxfordjournals.epirev.a018040 |
| [6] | Sugano, K., Tack, J., Kuipers, E.J., Graham, D.Y., El-Omar, E.M., Miura, S., et al. (2015) Kyoto Global Consensus Report on Helicobacter pylori Gastritis. Gut, 64, 1353-1367. https://doi.org/10.1136/gutjnl-2015-309252 |
| [7] | Kayali, S., Manfredi, M., Gaiani, F., Bianchi, L., Bizzarri, B., Leandro, G., Di Mario, F. and De’ Angelis, G.L. (2018) Helicobacter pylori, Transmission Routes and Recurrence of Infection: State of the Art. Acta Biomedica, 89, 72-76. |
| [8] | 中华医学会消化病学分会幽门螺杆菌学组. 2022中国幽门螺杆菌感染治疗指南[J]. 中华消化杂志, 2022, 42(11): 745-756. |
| [9] | Hu, Y., Zhu, Y. and Lu, N. (2017) Primary Antibiotic Resistance of Helicobacter Pylori in China. Digestive Diseases and Sciences, 62, 1146-1154. https://doi.org/10.1007/s10620-017-4536-8 |
| [10] | Chen, J., Li, P., Huang, Y., Guo, Y., Ding, Z. and Lu, H. (2022) Primary Antibiotic Resistance of Helicobacter pylori in Different Regions of China: A Systematic Review and Meta-Analysis. Pathogens, 11, Article 786. https://doi.org/10.3390/pathogens11070786 |
| [11] | Smith, K. and Leyden, J.J. (2005) Safety of Doxycycline and Minocycline: A Systematic Review. Clinical Therapeutics, 27, 1329-1342. https://doi.org/10.1016/j.clinthera.2005.09.005 |
| [12] | You, S., Tang, X., Zhou, J., Shen, Y., Song, X., Benghezal, M., et al. (2024) Minocycline/Amoxicillin-Based Bismuth Quadruple Therapy for Helicobacter pylori Eradication: A Pilot Study. Microorganisms, 12, Article 429. https://doi.org/10.3390/microorganisms12030429 |
| [13] | 陈志新, 赖祥丽, 胡华华. 复合乳酸菌联合四联疗法根除幽门螺杆菌的疗效观察[J]. 中国临床新医学, 2019, 12(9): 978-980. |
| [14] | Malfertheiner, P., Megraud, F., O’Morain, C.A., Gisbert, J.P., Kuipers, E.J., Axon, A.T., et al. (2017) Management of Helicobacter pylori Infection—The Maastricht V/Florence Consensus Report. Gut, 66, 6-30. https://doi.org/10.1136/gutjnl-2016-312288 |
| [15] | Fallone, C.A., Chiba, N., van Zanten, S.V., Fischbach, L., Gisbert, J.P., Hunt, R.H., et al. (2016) The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology, 151, 51-69.e14. https://doi.org/10.1053/j.gastro.2016.04.006 |
| [16] | Hooi, J.K.Y., Lai, W.Y., Ng, W.K., Suen, M.M.Y., Underwood, F.E., Tanyingoh, D., et al. (2017) Global Prevalence of Helicobacter pylori Infection: Systematic Review and Meta-Analysis. Gastroenterology, 153, 420-429. https://doi.org/10.1053/j.gastro.2017.04.022 |
| [17] | Hu, Y., Zhu, Y. and Lu, N. (2017) Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance. Frontiers in Cellular and Infection Microbiology, 7, Article ID: 168. https://doi.org/10.3389/fcimb.2017.00168 |
| [18] | Huang, Y., Chen, J., Ding, Z., Chen, X., Liang, X., Zeng, X., et al. (2023) Minocycline vs. Tetracycline in Bismuth-Containing Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicentre, Randomized Controlled Trial. Journal of Gastroenterology, 58, 633-641. https://doi.org/10.1007/s00535-023-01991-y |
| [19] | Song, Z., Suo, B., Zhang, L. and Zhou, L. (2016) Rabeprazole, Minocycline, Amoxicillin, and Bismuth as First‐Line and Second‐Line Regimens for Helicobacter Pylori Eradication. Helicobacter, 21, 462-470. https://doi.org/10.1111/hel.12313 |
| [20] | Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J.P., Liou, J., Schulz, C., et al. (2022) Management of Helicobacter pylori Infection: The Maastricht VI/Florence Consensus Report. Gut, 71, 1724-1762. https://doi.org/10.1136/gutjnl-2022-327745 |
| [21] | Wang, L., Li, Z., Tay, C.Y., Marshall, B.J., Gu, B., Tian, Y., et al. (2024) Multicentre, Cross-Sectional Surveillance of Helicobacter Pylori Prevalence and Antibiotic Resistance to Clarithromycin and Levofloxacin in Urban China Using the String Test Coupled with Quantitative PCR. The Lancet Microbe, 5, e512-e513. https://doi.org/10.1016/s2666-5247(24)00027-2 |
| [22] | Si, X., Zhang, L., Yang, S., Chen, X., Shi, Y., Lan, Y., et al. (2024) The Efficacy and Safety of Minocycline‐Containing Quadruple Therapies against Helicobacter Pylori Infection: A Retrospective Cohort Study. Infection and Drug Resistance, 17, 2513-2529. https://doi.org/10.2147/idr.s457618 |
| [23] | 王文卿. 复合乳酸菌联合四联疗法根治幽门螺杆菌感染疗效研究[J]. 现代医药卫生, 2019, 35(11): 1690-1691. |
| [24] | Eto, H., Suzuki, S., Kusano, C., Ikehara, H., Ichijima, R., Ito, H., et al. (2021) Impact of Body Size on First‐Line Helicobacter pylori Eradication Success Using Vonoprazan and Amoxicillin Dual Therapy. Helicobacter, 26, e12788. https://doi.org/10.1111/hel.12788 |
